A Study of Lasmiditan (LY573144) Over Four Migraine Attacks
NCT ID: NCT03670810
Last Updated: 2022-07-29
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
1633 participants
INTERVENTIONAL
2019-06-24
2021-07-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
NCT02439320
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
NCT04396236
A Study of Lasmiditan (LY573144) in Children Aged 6 to 17 With Migraine
NCT03988088
A Study of LY3451838 in Participants With Migraine
NCT04498910
Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine
NCT02605174
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
100 milligram (mg) Lasmiditan
Participants received one 100 mg Lasmiditan tablet with one 50 mg Lasmiditan matching placebo tablet and one 100 mg Lasmiditan matching placebo tablet to maintain blind. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.
Lasmiditan
Administered orally.
Placebo
Administered orally.
200 mg Lasmiditan
Participants received two 100 mg Lasmiditan tablets with one 50 mg Lasmiditan matching placebo tablet to maintain blind. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.
Lasmiditan
Administered orally.
Placebo
Administered orally.
Control 1 Sequence
Control 1:
Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 4.
Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 3.
Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.
Lasmiditan
Administered orally.
Placebo
Administered orally.
Control 2 Sequence
Control 2:
Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 3.
Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attack 4.
Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.
Lasmiditan
Administered orally.
Placebo
Administered orally.
100 mg Lasmiditan Maximum Extended Enrollment (MEE)
Participants received one 100 mg Lasmiditan tablet with one 50 mg Lasmiditan matching placebo tablet and one 100 mg Lasmiditan matching placebo tablet to maintain blind. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.
Lasmiditan
Administered orally.
Placebo
Administered orally.
200 mg Lasmiditan MEE
Participants received two 100 mg Lasmiditan tablets with one 50 mg Lasmiditan matching placebo tablet to maintain blind. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.
Lasmiditan
Administered orally.
Placebo
Administered orally.
Control 1 Sequence MEE
Control 1:
Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 4.
Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 3.
Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.
Lasmiditan
Administered orally.
Placebo
Administered orally.
Control 2 Sequence MEE
Control 2:
Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 3.
Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 4.
Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.
Lasmiditan
Administered orally.
Placebo
Administered orally.
Open Label Extension
Participants initially received 100 mg Lasmiditan at the first OLE visit, with flexible dosing (50, 100, or 200 mg) thereafter to optimize efficacy and tolerability.
Lasmiditan
Administered orally.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lasmiditan
Administered orally.
Placebo
Administered orally.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* History of disabling migraine for at least 1 year
* Migraine onset before the age of 50 years
* History of 3 to 8 migraine attacks per month (\<15 headache days per month) during the past 3 months
* MIDAS score ≥11
* Able and willing to complete an eDiary to record the details of each migraine attack treated with study drug
* Women of child-bearing potential must be using or willing to use a highly effective form of contraception
* Agree not to post any personal medical data or information related to the study on any website or social media site until the entire trial has completed
Exclusion Criteria
* History or evidence of hemorrhagic stroke, epilepsy, or any other condition placing the participant at increased risk of seizures
* History of recurrent dizziness and/or vertigo including benign paroxysmal positional vertigo, Meniere's disease, vestibular migraine, and other vestibular disorders
* History of diabetes mellitus with complications (diabetic retinopathy, nephropathy, or neuropathy)
* History of orthostatic hypotension with syncope
* Significant renal or hepatic impairment in the opinion of the investigator or if they meet hepatic monitoring criteria
* Participants who, in the investigator's judgment, are actively suicidal and therefore deemed to be at significant risk for suicide
* History, within past 12 months, of chronic migraine or other forms of primary or secondary chronic headache disorder (eg, hemicranias continua, medication overuse headache where headache frequency is ≥15 headache days per month)
* Use of more than 3 doses per month of either opioids or barbiturates
* Initiation of or a change in concomitant medication to reduce the frequency of migraine episodes within 3 months prior to screening
* Pregnant or breast-feeding women
* History of drug or alcohol abuse/dependence within 1 year prior to screening
* Any medical condition or clinical laboratory test which in the judgment of the investigator makes the participant unsuitable for the study
* Currently enrolled in any other clinical study involving an investigational product
* Relatives of, or staff directly reporting to, the Investigator
* Participants who are employees of the sponsor
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eli Lilly and Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Role: STUDY_DIRECTOR
Eli Lilly and Company
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rehabilitation & Neurological Services LLC
Huntsville, Alabama, United States
Barrow Neurological Institute
Phoenix, Arizona, United States
UCSD Altman Clinical & Translational Research Institute (ACTRI)
La Jolla, California, United States
Colorado Neurological Institute
Englewood, Colorado, United States
Georgetown University Hospital
Washington D.C., District of Columbia, United States
George Washington University Medical Center
Washington D.C., District of Columbia, United States
Diamond Headache Clinic
Chicago, Illinois, United States
Ochsner Medical Center - North Shore
Covington, Louisiana, United States
StudyMetrix Research, LLC
City of Saint Peters, Missouri, United States
Nevada Headache Institute
Las Vegas, Nevada, United States
Dent Neurological Institute
Amherst, New York, United States
Island Neuro Associates,PC
Plainview, New York, United States
Montefiore Headache Center
The Bronx, New York, United States
Northwest Clinical Research Center
Bellevue, Washington, United States
Universitätsklinik Innsbruck
Innsbruck, Tyrol, Austria
KH der Barmherzigen Schwestern Linz BetriebsGesmbH
Linz, Upper Austria, Austria
Christian-Doppler-Klinik
Salzburg, , Austria
AKH
Vienna, , Austria
Jessa Ziekenhuis
Hasselt, Limburg, Belgium
Algemeen Ziekenhuis St Jan Brugge
Bruges, , Belgium
Universitair Ziekenhuis Brussel
Brussels, , Belgium
Universitair Ziekenhuis Gent
Ghent, , Belgium
CHC MontLégia
Liège, , Belgium
Valdor - ISOSL CCV - Clinique des céphalées du Valdor - Neurology
Liège, , Belgium
Beijing Tiantan Hospital Affiliated to Capital Medical Univ
Beijing, Beijing Municipality, China
Xuanwu Hospital-Capital Medical University
Beijing, Beijing Municipality, China
The First Affiliated Hospital Chongqing Medical University
Chongqing, Chongqing Municipality, China
Guangzhou First People's Hospital
Guangzhou, Guangdong, China
The University of Hong Kong-Shenzhen Hospital
Shenzhen, Guangdong, China
Hebei General Hospital
Shijiazhuang, Hebei, China
First hospital affiliated to Zhengzhou University
Zhengzhou, Henan, China
Wuhan Union (Xiehe) Hospital
Wuhan, Hubei, China
Xiangya Hospital, Central South University
Changsha, Hunan, China
The First Affliated Hospital of Suzhou University
Suzhou, Jiangsu, China
Affiliated Hospital of Jiangsu University
Zhenjiang, Jiangsu, China
First Affiliated Hospital of Gannan Medical University
Ganzhou, Jiangxi, China
Pingxiang People's Hospital
Pingxiang, Jiangxi, China
No.2 Hospital Affiliated to Jilin University
Changchun, Jilin, China
Dalian Municipal Central Hospital Affiliated of Dalian Medical University
Dalian, Liaoning, China
Jiangsu Province Hospital
Nanjing, Nanjing, China
First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China
Shengli Oilfield Central Hospital
Dongying, Shandong, China
People's hospital of Rizhao
Rizhao, Shandong, China
HuaShan Hospital Affiliated To Fudan University
Shanghai, Shanghai Municipality, China
West China Hospital of Sichuan University
Chengdu, Sichuan, China
No 1 Affiliate Hospital of Kunming Medical College
Kunming, Yunnan, China
The Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
The First Affiliated Hospital of Wenzhou Medical College
Wenzhou, Zhejiang, China
Baotou Central Hospital
Baotou, , China
Peking Union Medical College Hospital
Beijing, , China
Chinese PLA General Hospital
Beijing, , China
The First Affiliated Hospital of Harbin Medical University
Harbin, , China
Tianjin Medical University General Hospital
Tianjin, , China
Clintrial, s.r.o.
Prague, Hl. M. Praha, Czechia
Neurologicka ambulance, Neurologie Brno s.r.o.
Brno, , Czechia
Brain-Soultherapy s.r.o
Kladno, , Czechia
DADO MEDICAL, s.r.o.
Prague, , Czechia
Neurologicka ordinace
Prague, , Czechia
Neurologicka ambulance Prerov
Přerov, , Czechia
CCBR-Alborg-DK
Aalborg, , Denmark
Glostrup Hospital
Glostrup Municipality, , Denmark
Center for Clinical and Basic Research -CCBR
Vejle, , Denmark
APHM Hôpital de la Timone
Marseille, , France
Centre Hospitalier Annecy Genevois - Site d'Annecy
Metz-Tessy, , France
Hopital Lariboisière
Paris, , France
CHU de Rouen Hopital Charles Nicolle
Rouen, , France
CHU St Etienne Hopital Nord
Saint-Etienne, , France
Synexus Clinical Research GmbH
Frankfurt am Main, Hesse, Germany
DRK-Kliniken Nordhessen
Kassel, Hesse, Germany
Gemeinschaftspraxis für Neurologie und Psychiatrie
Westerstede, Lower Saxony, Germany
Praxis Dr. Philipp Stude
Bochum, North Rhine-Westphalia, Germany
Synexus Clinical Research GmbH
Bochum, North Rhine-Westphalia, Germany
DataMed Klinische Studien GmbH
Cologne, North Rhine-Westphalia, Germany
Praxis für Neurologie und Psychiatrie
Essen, North Rhine-Westphalia, Germany
Synexus Clinical Research GmbH
Leipzig, Saxony, Germany
Universitätsklinikum Jena
Jena, Thuringia, Germany
Charité Universitätsmedizin Berlin
Berlin, , Germany
Synexus Clinical Research GmbH
Berlin, , Germany
Neurologische Praxis Eppendorf
Hamburg, , Germany
PANAKEIA - Arzneimittelforschung Leipzig GmbH
Leipzig, , Germany
Valeomed Kft.
Esztergom, Komárom-Esztergom, Hungary
SE Neurologiai Klinika
Budapest, , Hungary
Orszagos Idegtudomanyi Intezet
Budapest, , Hungary
Nizam's Institute of Medical Sciences
Hyderabad, Andhra Pradesh, India
Apollo Hospitals International Ltd.
Ahmedabad, Gujarat, India
Artemis Hospital
Gurgaon, Haryana, India
M S Ramaiah Medical College Hospital
Bangalore, Karnataka, India
Mangala Hospitals & Mangala Kidney Foundation
Mangalore, Karnataka, India
Kokilaben Dhirubhai Ambani Hospital &Medical Research Inst.
Mumbai, Maharashtra, India
HCG Manavata Cancer Centre
Nashik, Maharashtra, India
Deenanth Mangeshkar Hospital and Research Centre
Pune, Maharashtra, India
Gobind Ballabh Pant Hospital
New Delhi, , India
Sir Ganga Ram Hospital
New Delhi, , India
Istituto Neurologico Neuromed
Pozzilli, Isernia, Italy
Ospedale Bellaria
Bologna, , Italy
Istituto Neurologico Carlo Besta
Milan, , Italy
Fondazione Istituto Neurologico Nationale C. Mondino
Pavia, , Italy
Clinical Research Institute S C
Tlalnepantla, Edo de Mex, Mexico
Clinstile, S.A de C.V
Cuauhtémoc, Federal District, Mexico
CRI Centro Regiomontano de Investigacion S.C.
Monterrey, Nuevo León, Mexico
Hospital Universitario Dr. Jose Eleuterio Gonzalez
Monterrey, Nuevo León, Mexico
Medical Care and Research, S.A. de C.V.
Mérida, Yucatán, Mexico
Instituto de Investigaciones Aplicadas a la Neurociencia A.C
Durango, , Mexico
Eci Estudios Clinicos Int.
Puebla City, , Mexico
Centro de Atención e Investigación Cardiovascular del Potosí S.C.
San Luis Potosí City, , Mexico
Canisius-Wilhelmina Ziekenhuis
Nijmegen, Gelderland, Netherlands
Boerhaave Medisch Centrum
Amsterdam, , Netherlands
Isala Klinieken
Zwolle, , Netherlands
First Moscow State Medical University n.a. Sechenov
Moscow, , Russia
University Headache Clinic
Moscow, , Russia
Medis Priokskiy
Nizhny Novgorod, , Russia
Saint Petersburg State Medical University n.a. Pavlov I.P.
Saint Petersburg, , Russia
Hospital Universitari de Bellvitge
L'Hospitalet de Llobregat, Barcelona, Spain
Hospital Universitario Marques De Valdecilla
Santander, Cantabria, Spain
Clinica Universitaria De Navarra
Pamplona, Navarre, Spain
Hospital Universitari Vall d'Hebron
Barcelona, , Spain
Hospital Universitario La Paz
Madrid, , Spain
Hospital Universitario Virgen del Rocio
Seville, , Spain
Hospital Clínico Universitario de Valencia
Valencia, , Spain
Hospital Universitario La Fe de Valencia
Valencia, , Spain
Hospital Clinico Universitario de Valladolid
Valladolid, , Spain
H.C.U. Lozano Blesa
Zaragoza, , Spain
Kantonsspital Luzern
Lucerne, Canton of Lucerne, Switzerland
Kantonsspital St. Gallen
Sankt Gallen, Canton of St. Gallen, Switzerland
KopfwehZentrum Hirslanden Zürich
Zollikon, Canton of Zurich, Switzerland
Rehaclinic Bad Zurzach
Bad Zurzach, , Switzerland
Inselspital Bern
Bern, , Switzerland
Synexus Thames Valley Clinical Research Centre
Reading, Berkshire, United Kingdom
Hull Royal Infirmary
Hull, East Yorkshire, United Kingdom
Kings College Hospital
London, Greater London, United Kingdom
Re-Cognition Health Ltd
London, Greater London, United Kingdom
Synexus Manchester Clinical Research Centre
Manchester, Greater Manchester, United Kingdom
Synexus Lancashire Clinical Research Centre
Chorley, Lancashire, United Kingdom
Synexus Merseyside Clinical Research Centre
Liverpool, Merseyside, United Kingdom
Synexus Hexham General Hospital
Hexham, Northumberland, United Kingdom
Queen Elizabeth University Hospital
Glasgow, Scotland, United Kingdom
Synexus Wales Clinical Research Centre
Cardiff, South Glamorgan, United Kingdom
Synexus Scotland Clinical Research Centre
Glasgow, Strathclyde, United Kingdom
Re-Cognition Health Ltd
Guildford, Surrey, United Kingdom
Re-Cognition Health Ltd
Birmingham, West Midlands, United Kingdom
Synexus Midlands Clinical Research Center
Birmingham, Wstmid, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Komori M, Ozeki A, Tanji Y, Kamiki E, Krege JH, Li LQ, Suzuki S, Shibata M, Takeshima T. Long-term treatment with lasmiditan in patients with migraine: post hoc analysis of treatment patterns and outcomes from the open-label extension of the CENTURION randomized trial. J Headache Pain. 2024 Mar 25;25(1):43. doi: 10.1186/s10194-024-01745-y.
Blumenfeld A, Tepper SJ, Khanna R, Doty E, Vincent M, Miller SI. Serotonin syndrome in the acute treatment landscape of migraine: the lasmiditan experience. Front Neurol. 2023 Oct 27;14:1291102. doi: 10.3389/fneur.2023.1291102. eCollection 2023.
Ashina M, Roos C, Li LQ, Komori M, Ayer D, Ruff D, Krege JH. Long-term treatment with lasmiditan in patients with migraine: Results from the open-label extension of the CENTURION randomized trial. Cephalalgia. 2023 Apr;43(4):3331024231161745. doi: 10.1177/03331024231161745.
Zhou J, Luo G, Xu Y, Yang X, Pan X, Dong Z, Zhong S, Liu H, Ji F, Yu S. Safety Findings in Lasmiditan as a Novel Acute Treatment of Migraine in Chinese Patients: A Post Hoc Analysis of the Randomized Controlled Phase 3 CENTURION Trial. Adv Ther. 2022 Nov;39(11):5229-5243. doi: 10.1007/s12325-022-02291-2. Epub 2022 Sep 17.
MacGregor EA, Komori M, Krege JH, Baygani S, Vincent M, Pavlovic J, Igarashi H. Efficacy of lasmiditan for the acute treatment of perimenstrual migraine. Cephalalgia. 2022 Dec;42(14):1467-1475. doi: 10.1177/03331024221118929. Epub 2022 Aug 18.
Doty EG, Hauck PM, Krege JH, Komori M, Hake AM, Dong Y, Lipton RB. The Association Between the Occurrence of Common Treatment-Emergent Adverse Events and Efficacy Outcomes After Lasmiditan Treatment of a Single Migraine Attack: Secondary Analyses from Four Pooled Randomized Clinical Trials. CNS Drugs. 2022 Jul;36(7):771-783. doi: 10.1007/s40263-022-00928-y. Epub 2022 Jul 2.
Yu T, He L, Yang X, Zhou J, Luo G, Wang H, Zhao H, Hu Q, Ji F, Yu S. Efficacy and Safety of Lasmiditan as a Novel Acute Treatment in Chinese Patients with Migraine: A Subpopulation Analysis of the Randomized Controlled Phase 3 CENTURION Trial. Neurol Ther. 2022 Sep;11(3):1269-1283. doi: 10.1007/s40120-022-00369-1. Epub 2022 Jun 17.
Krege JH, Lipton RB, Baygani SK, Komori M, Ryan SM, Vincent M. Lasmiditan for Patients with Migraine and Contraindications to Triptans: A Post Hoc Analysis. Pain Ther. 2022 Jun;11(2):701-712. doi: 10.1007/s40122-022-00388-8. Epub 2022 Apr 26.
Tassorelli C, Bragg S, Krege JH, Doty EG, Ardayfio PA, Ruff D, Dowsett SA, Schwedt T. Safety findings from CENTURION, a phase 3 consistency study of lasmiditan for the acute treatment of migraine. J Headache Pain. 2021 Nov 6;22(1):132. doi: 10.1186/s10194-021-01343-2.
Reuter U, Krege JH, Lombard L, Gomez Valderas E, Krikke-Workel J, Dell-Agnello G, Dowsett SA, Buse DC. Lasmiditan efficacy in the acute treatment of migraine was independent of prior response to triptans: Findings from the CENTURION study. Cephalalgia. 2022 Jan;42(1):20-30. doi: 10.1177/03331024211048507. Epub 2021 Oct 13.
Ashina M, Reuter U, Smith T, Krikke-Workel J, Klise SR, Bragg S, Doty EG, Dowsett SA, Lin Q, Krege JH. Randomized, controlled trial of lasmiditan over four migraine attacks: Findings from the CENTURION study. Cephalalgia. 2021 Mar;41(3):294-304. doi: 10.1177/0333102421989232. Epub 2021 Feb 4.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
A Study of Lasmiditan (LY573144) Over Four Migraine Attacks
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H8H-MC-LAIJ
Identifier Type: OTHER
Identifier Source: secondary_id
2018-001661-17
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
17131
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.